<div class="docx-content">
<h1 class="text-2xl font-bold mt-8 mb-4">Whipple’s Disease</h1><h2 class="text-xl font-semibold mt-6 mb-3"><strong>1. Overview &amp; Taxonomy</strong></h2><ul><li><strong>Agent</strong>: <em>Tropheryma whipplei</em><ul><li>Gram-positive actinomycete (order <em>Actinomycetales</em>), related to <em>Actinomyces</em>.</li><li><strong>PAS-positive</strong> foamy macrophages in tissues.</li><li>Non-motile, non–acid-fast, slow-growing, fastidious.</li><li>Intracellular</li><li>aerobic</li></ul></li><li>Named after George Hoyt Whipple (1907).</li><li><strong>Epidemiology</strong>:<ul><li>Rare (~1/million/year).</li><li>Middle-aged Caucasian men (M:F ≈ 8–10:1).</li><li>Found in environment (sewage, soil); asymptomatic carriage possible, especially in endemic settings.</li><li>Possible occupational link: farmers, sewage workers.</li></ul></li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>2. Laboratory Microbiology</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>A) Morphology</strong></h3><ul><li>Small, rod-shaped Gram-positive bacilli (weakly Gram-staining).</li><li><strong>PAS-positive, diastase-resistant</strong> material in lamina propria macrophages.</li><li>Non–acid-fast on Ziehl–Neelsen (differentiates from <em>Mycobacterium avium</em> complex and <em>Nocardia</em>).</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>B) Culture</strong></h3><ul><li><strong>Fastidious</strong>: requires <strong>human fibroblast cell lines</strong> (e.g., HEL cells) or other eukaryotic systems.</li><li>No growth on standard bacteriological agar.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>C) Histology</strong></h3><ul><li><strong>Small bowel biopsy (duodenum/jejunum)</strong>:<ul><li>Villous blunting, lamina propria expanded by foamy macrophages packed with PAS-positive, diastase-resistant granules (glycoprotein-rich bacterial cell wall remnants).</li><li>Lymphatic dilation may be present.</li></ul></li><li><strong>Special stains</strong>: PAS key;</li><li>Immunohistochemistry with <em>T. whipplei</em>-specific antibodies improves sensitivity in equivocal PAS cases.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>D) Molecular Diagnostics</strong></h3><ul><li><strong>16S rRNA PCR</strong> (1991) or RT-PCR</li><li><strong>Best specimens</strong>:<ul><li>Intestinal mucosa (highest yield)</li><li>CSF (for CNS disease)</li><li>Synovial fluid</li><li>Heart valve tissue</li><li>Aqueous humour</li></ul></li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>G) Antimicrobial Susceptibility</strong></h3><ul><li>No standardised AST — requires intracellular culture.</li><li>In vitro susceptible to beta-lactams, tetracyclines, macrolides, co-trimoxazole.</li><li>Beta-lactams (esp. ceftriaxone, penicillin G) are bactericidal and penetrate tissues; co-trimoxazole and doxycycline penetrate CNS — basis for recommended regimens.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>3. Clinical Microbiology – Syndromes</strong></h2><h3 class="text-lg font-semibold mt-6 mb-3"><strong>A) Classic (Intestinal) Whipple’s Disease</strong></h3><ul><li><strong>Triad</strong>:<ul><li>Chronic diarrhoea/malabsorption (steatorrhoea, weight loss)</li><li>Arthralgia/arthritis (often migratory, large joints; may precede GI symptoms by years)</li><li>Fever (intermittent)</li></ul></li><li>Other: abdominal pain, lymphadenopathy, hyperpigmentation, anaemia.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>B) Extraintestinal Disease</strong></h3><ul><li><strong>Arthropathy</strong>: often initial presentation; non-erosive.</li><li><strong>Cardiac</strong>: culture-negative endocarditis (important differential with <em>Bartonella</em>, <em>Coxiella</em>).</li><li><strong>Neurological</strong>:<ul><li>Cognitive impairment/dementia-like syndrome</li><li>Supranuclear ophthalmoplegia</li><li>Myoclonus, seizures, ataxia</li><li>Untreated CNS involvement → high mortality.</li></ul></li><li><strong>Ocular</strong>: uveitis, vitritis, keratitis, retinitis.</li><li><strong>Pulmonary</strong>: pleuritis, chronic cough.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>4. Pathogenesis</strong></h2><ul><li>Chronic infection linked to <strong>defective Th1 immunity</strong> (reduced IFN-γ response).</li><li>Organism survives in macrophages → chronic granulomatous/foamy macrophage infiltrates.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>6. Treatment</strong></h2><p><strong>Principles</strong>:</p><ul><li>Initial bactericidal IV phase → prolonged oral maintenance with CNS-penetrating agent to prevent relapse.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>A) Standard regimen</strong></h3><ol><li><strong>Initial (2 weeks)</strong>:<ol><li><strong>IV ceftriaxone 2 g od</strong><br /> <strong>OR</strong></li><li><strong>IV penicillin G</strong> 2–4 MU q4h + streptomycin 1 g IM od</li></ol></li><li><strong>Maintenance (≥12 months; ≥24 months in CNS disease)</strong>:<ol><li><strong>Co-trimoxazole 160/800 mg bd</strong></li></ol></li></ol><h3 class="text-lg font-semibold mt-6 mb-3"><strong>B) Alternatives</strong></h3><ul><li><strong>Doxycycline 100 mg bd + hydroxychloroquine 200 mg tds</strong> for ≥12–18 months.</li></ul><h3 class="text-lg font-semibold mt-6 mb-3"><strong>C) Monitoring</strong></h3><ul><li>PCR on follow-up biopsy or CSF if initially positive.</li><li>Late relapse possible years after apparent cure.</li></ul><h2 class="text-xl font-semibold mt-6 mb-3"><strong>Quick Reference Table</strong></h2><table><tr><td><p><strong>Feature</strong></p></td><td><p><strong><em>Tropheryma whipplei</em></strong></p></td></tr><tr><td><p>Gram stain</p></td><td><p>Weak Gram-positive coccobacillus</p></td></tr><tr><td><p>Acid-fast</p></td><td><p>Negative</p></td></tr><tr><td><p>Special stains</p></td><td><p>PAS-positive, diastase-resistant macrophages</p></td></tr><tr><td><p>Culture</p></td><td><p>Cell culture only (reference/research)</p></td></tr><tr><td><p>Common presentation</p></td><td><p>Malabsorption, arthritis, fever</p></td></tr><tr><td><p>Extraintestinal</p></td><td><p>CNS, cardiac, ocular, pulmonary</p></td></tr><tr><td><p>Diagnosis</p></td><td><p>Biopsy histology + PCR</p></td></tr><tr><td><p>First-line treatment</p></td><td><p>IV ceftriaxone × 2 wks → co-trimoxazole ≥12 mo</p></td></tr><tr><td><p>Prognosis</p></td><td><p>Fatal if untreated; CNS relapse risk high</p></td></tr></table>
</div>